600789 Stock Overview
Operates as a pharmaceutical company in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Shandong Lukang Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.81 |
| 52 Week High | CN¥10.67 |
| 52 Week Low | CN¥5.04 |
| Beta | 0.30 |
| 11 Month Change | 6.92% |
| 3 Month Change | 21.18% |
| 1 Year Change | 10.13% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600789 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 3.8% | -1.8% | -2.6% |
| 1Y | 10.1% | -7.0% | 4.2% |
Return vs Industry: 600789 exceeded the CN Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: 600789 exceeded the CN Market which returned 4.2% over the past year.
Price Volatility
| 600789 volatility | |
|---|---|
| 600789 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600789 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600789's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 6,484 | Kun Dong | www.lkpc.com |
Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products.
Shandong Lukang Pharmaceutical Co.,Ltd. Fundamentals Summary
| 600789 fundamental statistics | |
|---|---|
| Market cap | CN¥7.92b |
| Earnings (TTM) | CN¥400.68m |
| Revenue (TTM) | CN¥6.08b |
19.8x
P/E Ratio1.3x
P/S RatioIs 600789 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600789 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.08b |
| Cost of Revenue | CN¥4.70b |
| Gross Profit | CN¥1.38b |
| Other Expenses | CN¥980.88m |
| Earnings | CN¥400.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 22.72% |
| Net Profit Margin | 6.59% |
| Debt/Equity Ratio | 69.5% |
How did 600789 perform over the long term?
See historical performance and comparison